Matthew F Mart, Leanne M Boehm, Amy L Kiehl, Michelle N Gong, Atul Malhotra, Robert L Owens, Babar A Khan, Margaret A Pisani, Gregory A Schmidt, R Duncan Hite, Matthew C Exline, Shannon S Carson, Catherine L Hough, Peter Rock, Ivor S Douglas, Daniel J Feinstein, Robert C Hyzy, William D Schweickert, David L Bowton, Andrew Masica, Onur M Orun, Rameela Raman, Brenda T Pun, Cayce Strength, Mark L Rolfsen, Pratik P Pandharipande, Nathan E Brummel, Christopher G Hughes, Mayur B Patel, Joanna L Stollings, E Wesley Ely, James C Jackson, Timothy D Girard
BACKGROUND: Delirium is common during critical illness and is associated with long-term cognitive impairment and disability. Antipsychotics are frequently used to treat delirium, but their effects on long-term outcomes are unknown. We aimed to investigate the effects of antipsychotic treatment of delirious, critically ill patients on long-term cognitive, functional, psychological, and quality-of-life outcomes. METHODS: This prespecified, long-term follow-up to the randomised, double-blind, placebo-controlled phase 3 MIND-USA Study was conducted in 16 hospitals throughout the USA...
August 2024: Lancet Respiratory Medicine